MDGL Q3 2018 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$24,000

Operating Income

-$11M

Net Income

-$9M

EPS (Diluted)

$-0.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$490M

Total Liabilities

$7M

Stockholders' Equity

$483M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$24,000	-$9,000	-166.7%
Operating Income	-$11M	-$9M	-31.2%
Net Income	-$9M	-$8M	-1.8%